Safety Alerts
Updates on impurities in high blood pressure medicines
Audiences
Consumer
Healthcare professional
Industry member
Product type
Therapeutic Products
2 October 2019
This article has been migrated from an earlier version of the site and may display formatting inconsistencies.
HSA would like to update the public on our actions and investigations into the potential contamination of angiotensin II receptor blockers (ARBs) with nitrosamine impurities such as N-Nitrosodimethylamine (NDMA), N-Nitrosodiethylamine (NDEA), N-Nitroso-N-methyl-4-aminobutyric acid (NMBA). The ARB class of medicines is used for the control of high blood pressure. Please refer below for the latest updates.
Table caption
Types of communication | Date of release | Title |
|---|---|---|
Press Release | 28 Mar 2019 | HSA Recalls Three Brand of Losartan Medicines from Hetero Labs Ltd |
HSA Update 3 | 07 Mar 2019 | HSA Updates on Overseas Recall of Angiotensin II Receptor Blockers (NMBA impurity) |
HSA Update 2 | 19 Dec 2018 | HSA Updates on Overseas Recall of Angiotensin II Receptor Blockers (NDMA and NDEA impurities) |
HSA Update 1 | 29 Aug 2018 | HSA Updates on Overseas Recall of Valsartan Medicines (NDMA impurity) |
Testing methods for NDMA, NDEA and NMBA in Angiotensin II Receptors Blockers
This section features test methods developed by the Health Sciences Authority for the identification and determination of nitrosamine impurities in angiotensin II receptor blockers (ARBs).
The testing methods below provide options and guidance for the industry to detect nitrosamine impurities in ARB medicinal products. These methods should be validated by users to ensure they are fit for their intended use.
Table caption
Date of release | Title |
|---|---|
1 March 2021 |